CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
CC-486drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02269943
NCT02269943Phase 2Completed

A Phase 2, Multicenter, International, Single Arm Study To Assess The Safety And Efficacy Of Single Agent Cc-486 (Oral Azacitidine) In Previously Treated Subjects With Locally Advanced Or Metastatic Nasopharyngeal Carcinoma

Celgene·interventional·Posted Oct 21, 2014·Updated Dec 12, 2018

In Brief

A Phase 2 clinical trial evaluating CC-486 for Nasopharyngeal Neoplasms. Completed, enrolled 36 participants across 25 sites in 9 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including platinum-based chemotherapy. Participants will be enrolled according to a Simon two-stage design; if the predefined activity is met (\>4 responses \[complete response; partial response {CR/PR}\] out of the first 17 evaluable participants based on independent radiological assessment), then the study will continue to enroll an additional 34 participants. If 4 or less responses out of 17 are observed, then the study enrollment will be stopped.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, France, Greece, Italy, Singapore, Spain, Taiwan, Tunisia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 21, 2014
Enrollment StartFeb 13, 2015
Primary CompletionApr 20, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.7 years ago

Interventions

CC-486drug